Jul 18, 2008 by Brian Orelli, PhDWhat Strikes Against Stryker?High growth isn't enough to impress investors.
Jul 18, 2008 by Brian Orelli, PhDFoolish Forecast: How Quickly Can Merck Turn It Around?Views you can use to get clues on the news.
Jul 17, 2008 by Brian Orelli, PhDInvestors Yawn at Abbott Labs' GrowthWhat's a company gotta do to get some investor love around here?
Jul 16, 2008 by Brian Orelli, PhDJ&J's Lesson to Investors: Diversify!J&J gives investors something to cheer about.
Jul 15, 2008 by Brian Orelli, PhDWill a New Use Help Schering-Plough's Near-Blockbuster Drug?Delaying relapses probably won't be enough to get its Pegintron approved as a treatment for melanoma.
Jul 14, 2008 by Brian Orelli, PhDTeva Gets a Taste of Its Own MedicineDrug companies attack the generic-drug makers' patents.
Jul 14, 2008 by Brian Orelli, PhDFoolish Forecast: J&J Trudges AlongViews you can use to get clues on tomorrow's news.
Jul 11, 2008 by Brian Orelli, PhDPfizer Looking at a Level Playing FieldAn advisory panel says that epilepsy drugs don't need a black-box warning.
Jul 10, 2008 by Brian Orelli, PhDThe Death of the Approvable LetterThe name's changing, but for investors, little else will.
Jul 9, 2008 by Brian Orelli, PhDA Drug to Fertilize Schering-Plough's Growth?A fertility treatment displays promising results in a phase 3 trial.
Jul 8, 2008 by Brian Orelli, PhDNot Teva's ForteThe drugmaker's Copaxone for multiple sclerosis fails to show a benefit at double strength.
Jul 8, 2008 by Brian Orelli, PhDNow That's the Way to Spin Off a CompanySell off the spin-off for more than the company was worth before the breakup.
Jul 7, 2008 by Brian Orelli, PhDda Vinci Heads to ChinaIntuitive Surgical's surgical system gets a thumbs-up from the Chinese government.
Jul 2, 2008 by Brian Orelli, PhDWounded by a Partner?If Johnson & Johnson sells its wound-care business, its partner could lose big.
Jul 1, 2008 by Brian Orelli, PhDAs the FDA Generics Office TurnsThe FDA reluctantly gives Teva a 180-day exclusive period to sell generic Risperdal.
Jun 30, 2008 by Brian Orelli, PhDA Drug to End Merck's Headache?Merck presents promising data for its phase 3 migraine drug.
Jun 30, 2008 by Brian Orelli, PhDJohnson & Johnson Grows Up a LittleIts Concerta for attention-deficit disorder is approved for use in adults.
